Clin Assoc Prof Ang Mei-Kim

Dr Ang Mei-Kim is a Senior Consultant working at the Division of Medical Oncology at the National Cancer Centre Singapore. Her clinical interests are in the treatment of patients with head and neck cancers as well as thoracic malignancies. She is also involved in several ongoing clinical trials and research projects in these cancers. Dr Ang is part of the core faculty for the Medical Oncology senior residency training program.

• Specialist Training Accreditation (Medical Oncology)
  Singapore
  Academy of Medicine
  2008
• Member, Royal College of Physicians
  United Kingdom
  Royal College of Physicians, UK
  2004
• Bachelor of Medicine, Bachelor of Surgery
  United Kingdom
  University of Cambridge
  2000
• Bachelor of Arts
  United Kingdom
  University of Cambridge
  1998
  

• Senior Consultant and Head of Lung, Head and Neck and Genitourinary Oncology Service, Division of Medical Oncology, National Cancer Centre Singapore
• Core Faculty Member for Medical Oncology Senior Residency Program
• Pharmacy and Therapeutics Committee Member, National Cancer Centre Singapore
• Lung Cancer Service Line Development committee

• Singapore Health Quality Service Gold Award
  2021
• Singapore Health Quality Service Gold Award
  2020
• Outstanding Faculty Award - Singhealth RISE awards
  2020
• Minister for Health Award for National Medication Safety Committee
  2019
• Outstanding Faculty Award - Singhealth RISE awards
  2017
• Outstanding Faculty Award - Singhealth RISE awards
  2016
• Outstanding Faculty Award - Singhealth RISE awards
  2015
• Publish! Award - Singhealth
  2012
• Singapore Health Quality Service Silver Award
  2010
• Scholarship award for Associate investigators - Singapore Millenium Foundation
  2007
• Registrar Service Award - Singapore General Hospital
  2007

• Prognostic markers in Head and neck squamous cell carcinoma
• Development of clinical trials in head and neck squamous cell carcinoma
• Clinical trials in lung cancer
  

• A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients, 2014 
• A phase II, multicenter, three-cohort of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/ metastatic disease, 2003
  

​

1. Chua KP, Teng YHF, Tan AC, et al. Integrative Profiling of T790M Negative EGFR Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. Clin Cancer Res 2021; 27(21): 5939-5950.
2. Seet AOL, Tan AC, Tan TJ, et al. Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study- An Asian Tertiary Cancer Centre Experience. JCO Precision Oncology 2021; 5:PO.20.00261.
3. Ang MK, Montoya JE, Tharavichitkul E, et al. Phase II study of nimotuzumab (TheraCim-hR3) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Head & Neck 2021; 43(5): 1641-1651.
4. Lek AM, Li K, Tan OX, et al. Pairing a prognostic target with potential therapeutic strategy for head and neck cancer. Oral Oncology 2020; 111: 105035.
5. Tan AC, Seet AOL, Lai GGY, et al. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. Journal of Thoracic Oncology 2020; 15(12): 1928-1934.
6. Chua KLM, Fehlings M, Yeo ELL, et al. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. International Journal of Radiation Oncology, Biology, Physics 2020; 108(1): 70-80.
7. Tan AC, Lai GGY, Tan GS, et al. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer 2020; 139: 207-215.
8. Ang MK; Mok TSK. Twenty-five years of Respirology: Advances in lung cancer. Respirology 2020; 25(1): 26-31.
9. Lai GGY, Lim TH, Lim J, et al. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2019; 37(11): 876-884.
10. Fong PY, Tan SH, Lim DWT, et al. Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma. PLoS One 2019; 14(11): e0224665
11. Tan WL, Ng QS, Lim C, et al. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer 2018; 18(1): 1198.
12. Toh CK, Ong WS, Lim WT, et al. A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival. Clinical Lung Cancer 2018; 19(5): e539-e550.
13. Ong CAJ, Shannon NB, Mueller S, et al. A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancer. Oncotarget 2017; 8(45): 79556-79566.
14. Tan DSW, Chong FT, Leong HS, et al. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nature Medicine 2017; 23(10): 1167-1175.
15. Marvalim C, Wong JXG, Sutiman N, et al. Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients. Pharmacogenetics and Genomics 2017; 27(3): 120-123.
16. Sutiman N, Tan SW, Tan EH, et al. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. Journal of Thoracic Oncology 2017; 12(3): 529-538.
17. Sutiman N, Zhang ZX, Tan EH, et al. Phase I study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC) Using Two Different Schedules. PLoS One 2016; 11(5): e0154316.
18. Tan CL, Lim TH, Lim TKH, et al. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. Oncotarget 2016; 7(17):23251-23262.
19. Tan WL, Tan EH, Lim DWT, Ng QS, Tan DSW, Jain A, Ang MK. Advances in systemic treatment for nasopharyngeal carcinoma. Chin Clin Oncol 2016; 5(2): 21.
20. Tay GCA, Iyer NG, Ong WS, et al. Outcomes and Prognostic Factors of Radiation-Induced and De Novo Head and Neck Squamous Cell Carcinomas. Otolaryngology- Head and Neck Surgery 2016; 154(5): 880-887.
21. Jain A, Lim C, Gan EMJ, et al. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS One 2015; 10(5): e0123587.
22. Tan EH, Tan DSW, Li WY, et al. Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. Lung Cancer 2015; 88(3): 289-296.
23. Tan T, Lim WT, Fong KW, et al. Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. International Journal of Radiation Oncology, Biology, Physics 2015; 91(5): 952-960.
24. Iyer NG, Tan DSW, Tan VKM, et al. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer 2015; 121(10): 1599-1607.
25. Ang SH, Haaland B, Acharyya S, et al. Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma. Head & Neck 2015; 37(11):1650-1659.
26. Tham CK, Chew MH, Soong R, et al. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. Cancer 2014; 120(20): 3131-3141.
27. Tan DSW, Camilleri-Broët S, Tan EH, et al. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. International Journal of Cancer 2014; 135(5):1092-1100.
28. Choo S P, Chowbay B, Ng QS, et al. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. European Journal of Cancer 2013; 49(5):999-1008.
29. Vonn W, Yin XY, Wilkerson MD, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One 2013; 8(2): e56823.
30. Patel MR, Zhao Ni, Ang MK, et al. ERCC1 protein expression is associated with differential survival in oropharyngeal head and neck squamous cell carcinoma. Otolaryngology- Head and Neck Surgery 2013; 149(4):587-595.
31. Ng KP, Hillmer AM, Chuah CTH, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine 2012; 18(4):521-528.
32. Chong LYZ, Cheok PY, Tan WJ, et al. Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification. Breast Cancer Research and Treatment 2012; 132(1):143-151.
33. Tan EH, Goh C, Lim WT, et al. Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Annals of Oncology 2012; 23(4):1010-1016.
34. Zhao N, Ang MK, Yin X-Y, et al. Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer. British Journal of Cancer 2012; 107(3):482-490.
35. Ngeow J, Lim WT, Leong SS, et al. Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. Annals of Oncology 2011; 22(3):718-722.
36. Ang MK, Ooi AS, Thike AA, et al. Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression. Breast Cancer Research and Treatment 2011; 129(2):319-329.
37. Tan S-Y, Ooi A-S, Ang M-K, et al. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia 2011; 25(3):555-557.
38. Ang MK, Patel MR, Yin XY, et al. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2011; 17(20):6542-6552.
39. Ang MK, Hee SW, Quek R, et al. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Annals of Hematology 2009; 88(5):417-424.
40. Lim ST, Hee SW, Quek R, et al. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. European Journal of Haematology 2008; 80(1):55-60.
41. Ngo L, Hee S-W, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. Leukemia & Lymphoma 2008; 49(3):462-469.
42. Ang MK, Poon D, Foo K-F, et al.  A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematology Oncology and Stem Cell Therapy 2008; 1(3):159-165.